Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE PSEUDOEPHEDRINE HYDROCHLORIDE versus WYAMINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE PSEUDOEPHEDRINE HYDROCHLORIDE versus WYAMINE SULFATE.
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE vs WYAMINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist; pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
Wyamine sulfate (mephentermine sulfate) is a sympathomimetic amine that acts primarily by releasing norepinephrine from presynaptic nerve terminals, with direct alpha- and beta-adrenergic receptor agonist activity. It causes vasoconstriction and positive inotropic effects, increasing cardiac output and blood pressure.
One tablet (fexofenadine HCl 60 mg / pseudoephedrine HCl 120 mg) orally every 12 hours. Maximum 2 tablets per day.
Intramuscular injection: 15-30 mg as a single dose; may repeat in 10-15 minutes if needed. Maximum total dose: 60 mg.
None Documented
None Documented
Fexofenadine: 14.4 hours. Pseudoephedrine: 5-8 hours, prolonged in renal impairment.
Terminal elimination half-life is 6-8 hours in adults with normal renal function (CrCl >90 mL/min).
Fexofenadine: 80% unchanged in feces, 11% in urine. Pseudoephedrine: 70-90% unchanged in urine.
Primarily renal; 90% excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<5%).
Category A/B
Category C
Sympathomimetic
Sympathomimetic